Illumina, Inc.

ILMN Healthcare Diagnostics & Research

Illumina, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 0.66% from fiscal 2024.

Revenue
+4.15%
EPS
+49.0%
Free cash flow
+49.8%
Total debt
+80.0%

Quarter to September 2026, against a year earlier

209.82 16.72 −7.38%
Market cap
$31.5B
P/E
35.6×
Fwd P/E
46.4×
Dividend yield
—
F-score
8/9
Altman Z
4.39
Beneish M
−2.51
Dividend safety
n/a

Illumina, Inc. (ILMN) Current ratio

Alert me on Current ratio

Illumina, Inc.'s current ratio at the end of the quarter to 30 September 2026 was 2.6×, up 0.6× from fiscal 2025 (2.1×). Over the past ten years it has ranged from 1.3× (fiscal 2022) to 6.7× (fiscal 2019); the current reading is higher than 36% of that period. That is above the Diagnostics & Research industry median of 2.3× and below the Healthcare sector median of 3.1×.

Current ratio, annual

Embed this chart

Annual newest first

Period Current ratio Change
FY2025 2.1× 16.91%
FY2024 1.8× 6.81%
FY2023 1.7× 29.40%
FY2022 1.3× (48.26%)
FY2021 2.5× (31.12%)
FY2020 3.6× (46.16%)
FY2019 6.7× 168.92%
FY2018 2.5× (37.69%)
FY2017 4.0× 21.49%
FY2016 3.3× (4.27%)

Quarterly newest first

Period Current ratio Change
Sep 2026 2.6× 46.19%
Jun 2026 1.8× 2.72%
Mar 2026 1.7× (15.74%)
Dec 2025 2.1× 45.61%
43 more quarters

Against its own ten years

Low 1.3× High 6.7×
Ten-year median 2.5×
Current reading's percentile 36

Current ratio against peers

What Current ratio is

Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.

Current Assets (Total) ÷ Current Liabilities (Total)

The full definition of Current ratio →

More on ILMN